STOCK TITAN

Johnson & Johnson - JNJ STOCK NEWS

Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.

Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.

In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.

Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.

With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.

Rhea-AI Summary
Johnson & Johnson (JNJ) will participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) with Joaquin Duato, Chairman and CEO, representing the Company. The live audio webcast will be available to investors on May 29th, at 1:30 pm Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
conferences
-
Rhea-AI Summary
Johnson & Johnson (JNJ) announces its 62nd consecutive year of dividend increase, raising the quarterly dividend by 4.2% to $1.24 per share. This marks a significant milestone for the company, with the annual dividend now at $4.96 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
dividends
-
Rhea-AI Summary
Johnson & Johnson (JNJ) reported a 2.3% sales growth to $21.4 billion in Q1 2024, with adjusted EPS increasing by 12.4%. The company raised its full-year operational sales and adjusted EPS guidance. Operational sales for Innovative Medicine and MedTech segments showed positive growth. Notable products driving growth include DARZALEX, ERLEADA, and CARVYKTI in Oncology, and electrophysiology products in MedTech.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
Rhea-AI Summary
Johnson & Johnson reported a 2.3% sales growth to $21.4 billion in Q1 2024, with operational growth of 3.9% and adjusted EPS increase of 12.4%. The company raised its Full-Year 2024 operational sales and adjusted EPS guidance. Innovative Medicine and MedTech segments showed positive growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
-
Rhea-AI Summary
Johnson & Johnson (JNJ) to participate in the 2024 RBC Capital Markets Global Healthcare Conference on May 15th, with Tim Schmid representing the company. The live webcast will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences
-
Rhea-AI Summary
Johnson & Johnson (JNJ) receives FDA approval for CARVYKTI® for the treatment of relapsed or refractory multiple myeloma, offering patients a potential treatment-free period as early as first relapse. The approval is based on positive results from the Phase 3 CARTITUDE-4 study, showing a 59% reduction in the risk of disease progression or death compared to standard therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
Rhea-AI Summary
Johnson & Johnson (JNJ) to acquire Shockwave Medical, Inc. (SWAV) for $13.1 billion, enhancing its position in cardiovascular intervention. The acquisition aims to drive sales growth, improve patient outcomes, and accelerate operating margin. Shockwave's IVL technology for calcified CAD and PAD treatment aligns with JNJ's focus on cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
-
Rhea-AI Summary
Johnson & Johnson (JNJ) received an unsolicited mini-tender offer from TRC Capital Investment to purchase up to 1 million shares at $151.23 per share, 4.12% lower than the previous closing price. JNJ advises shareholders not to tender their shares due to the offer being below market price and subject to conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none
-
Rhea-AI Summary
Johnson & Johnson (JNJ) will participate in the BofA Securities Health Care Conference with John Reed representing the company. The live audio webcast will be available for investors on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
Rhea-AI Summary
Johnson & Johnson (JNJ) will host a conference call to review first-quarter results, featuring top executives. Investors can access the webcast and presentation material on the company's website. The press release provides details on accessing the call and future earnings calls.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences earnings

FAQ

What is the current stock price of Johnson & Johnson (JNJ)?

The current stock price of Johnson & Johnson (JNJ) is $154 as of November 15, 2024.

What is the market cap of Johnson & Johnson (JNJ)?

The market cap of Johnson & Johnson (JNJ) is approximately 353.3B.

What are the main business segments of Johnson & Johnson?

Johnson & Johnson operates through three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products.

What recent developments have there been in Johnson & Johnson's pharmaceutical division?

Recently, Johnson & Johnson received expanded FDA approval for CARVYKTI®, a therapy for multiple myeloma, based on positive Phase 3 study results.

What products are included in Johnson & Johnson’s consumer health segment?

The consumer health segment includes products in baby care, beauty, oral care, over-the-counter drugs, and women's health.

What is CARVYKTI®?

CARVYKTI® is a one-time infusion therapy for multiple myeloma, recently approved for expanded use due to its efficacy in delaying disease progression.

What percentage of Johnson & Johnson's revenue is generated in the United States?

Over half of Johnson & Johnson’s total revenue is generated in the United States.

What is the focus of Johnson & Johnson’s medical devices segment?

The medical devices segment focuses on orthopedics, surgical instruments, and vision care.

What changes are happening with Johnson & Johnson’s consumer health division?

The consumer health division is being divested in 2023 and will operate under the new name Kenvue.

How does Johnson & Johnson contribute to global healthcare?

Johnson & Johnson develops innovative solutions to prevent, treat, and cure complex diseases, aiming to improve global health.

Where can I find more information about Johnson & Johnson?

More information about Johnson & Johnson can be found on their official website at www.jnj.com.

What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?

The pharmaceutical division focuses on immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases.

Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Stock Data

353.35B
2.41B
0.09%
72.76%
0.78%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW BRUNSWICK